Comparison
Here's a high-level comparison based on available trial data (averages; individual results vary). Focus is on non-diabetic adults with obesity, as trials often include ages up to 75, though sedentary-specific data is extrapolated from general older adult studies.
Aspect | CagriSema | Retatrutide + Cagrilintide | Just Cagrilintide |
---|
Average Weight Loss | 22.7% at 68 weeks | ~24%+ (theoretical combo; retatrutide alone 24% at 48 weeks) | 6-10.8% at 26 weeks |
Efficacy for 20lb Goal | High (easily achievable; superior to semaglutide alone) | Very high, but unproven combo | Moderate (may need longer use or adjuncts) |
Safety in Elderly/Sedentary | Generally good; GI-dominant side effects, but muscle loss risk without activity | Higher AE risk (e.g., heart rate increase); compounding concerns | Gentler profile, but less studied alone |
Status as of 2025 | Phase 3 complete; promising for approval | Experimental combo; retatrutide in Phase 3 alone | Investigational; better in combos |
Fit for Prior GLP-1 Users | Builds on your experience; enhanced satiety | Novel mechanisms; potential for more side effects | Milder, but may feel underwhelming |
Based on the data, if I had to suggest one option for someone in your situation (sedentary, 63, prior GLP-1 use, modest 20lb goal), I'd lean toward CagriSema.
It offers robust efficacy (well above your target) with a safety profile that's an evolution of what you've used before, without venturing into unapproved combinations.
Retatrutide alone shows slightly higher weight loss potential, but adding cagrilintide lacks solid evidence and could introduce unnecessary risks, especially for older adults where simplicity and monitoring are key. Just cagrilintide might not hit your goal efficiently.
Overall, these agents work best with gradual activity increases (e.g., walking) to mitigate muscle loss, and regular check-ins for side effects. Again, please discuss with your doctor—they might also recommend starting low-dose or combining with nutrition counseling.